Zibotentan

Zibotentan
Names
	Preferred IUPAC name N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
	Other names ZD4054
Identifiers
CAS Number	186497-07-4 ;
3D model (JSmol)	Interactive image;
ChemSpider	8085875 ;
ECHA InfoCard	100.171.075
IUPHAR/BPS	3539;
PubChem CID	9910224;
UNII	8054MM4902 ;
	InChI InChI=1S/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) Key: FJHHZXWJVIEFGJ-UHFFFAOYSA-N ; InChI=1/C19H16N6O4S/c1-12-10-21-17(19(23-12)28-2)25-30(26,27)15-4-3-9-20-16(15)13-5-7-14(8-6-13)18-24-22-11-29-18/h3-11H,1-2H3,(H,21,25) Key: FJHHZXWJVIEFGJ-UHFFFAOYAL;
	SMILES O=S(=O)(Nc1ncc(nc1OC)C)c4cccnc4c3ccc(c2nnco2)cc3;
Properties
Chemical formula	C19H16N6O4S
Molar mass	424.44 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.^[1] It is an endothelin receptor antagonist.^[2]

Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.

It failed a phase III clinical trial for prostate cancer,^[3] but other trials are planned.^[4] Tolerability of zibotentan plus docetaxel has been evaluated.^[5]

Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,^[6] bone metastasis, and heart failure.^[7]

References[edit]

^ James and Growcott (2009). "Drugs of the Future".
^ Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T (2011). "Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies". BMC Clin Pharmacol. 11: 3. doi:10.1186/1472-6904-11-3. PMC 3070638. PMID 21414193.
^ "AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech". www.fiercebiotech.com. Retrieved 16 April 2018.
^ "Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN". GEN. 28 September 2010. Retrieved 16 April 2018.
^ Trump DL, Payne H, Miller K, et al. (September 2011). "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer". Prostate. 71 (12): 1264–75. doi:10.1002/pros.21342. PMID 21271613. S2CID 29707062.
^ "A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.
^ "Zibotentan - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.

External links[edit]

Zibotentan

[1] James and Growcott (2009). "Drugs of the Future".

[pmid21414193-2] Tomkinson H, Kemp J, Oliver S, Swaisland H, Taboada M, Morris T (2011). "Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies". BMC Clin Pharmacol. 11: 3. doi:10.1186/1472-6904-11-3. PMC 3070638. PMID 21414193.

[3] "AZ's zibotentan flunks late-stage prostate cancer trial - FierceBiotech". www.fiercebiotech.com. Retrieved 16 April 2018.

[tf-4] "Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures - GEN". GEN. 28 September 2010. Retrieved 16 April 2018.

[pmid21271613-5] Trump DL, Payne H, Miller K, et al. (September 2011). "Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer". Prostate. 71 (12): 1264–75. doi:10.1002/pros.21342. PMID 21271613. S2CID 29707062.

[6] "A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.

[7] "Zibotentan - AdisInsight". adisinsight.springer.com. Retrieved 16 April 2018.

[1]

[2]

[3]

[4]

[5]

[6]

[7]